ENGN Insider Trading
Insider Ownership Percentage: 10.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
enGene Share Price & Price History
Current Price: $6.06
Price Change: ▲ Price Increase of +0.04 (0.66%)
As of 11/7/2025 05:00 PM ET
enGene Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/7/2024 | Growth Opportunities F Forbion | Major Shareholder | Buy | 11,844 | $6.55 | $77,578.20 | 2,469,833 | |
| 10/4/2024 | Growth Opportunities F Forbion | Major Shareholder | Buy | 5,997 | $6.54 | $39,220.38 | 2,457,989 | |
| 10/2/2024 | Growth Opportunities F Forbion | Major Shareholder | Buy | 10,153 | $6.37 | $64,674.61 | 2,446,223 | |
| 9/30/2024 | Growth Opportunities F Forbion | Major Shareholder | Buy | 341,332 | $6.34 | $2,164,044.88 | 2,400,791 | |
| 9/27/2024 | Growth Opportunities F Forbion | Major Shareholder | Buy | 41,639 | $5.97 | $248,584.83 | 2,059,459 | |
| 9/27/2024 | Ronald Harold Wilfred Cooper | CEO | Buy | 10,000 | $5.70 | $57,000.00 | 10,000 | |
| 4/22/2024 | De Solidarite Des Travai Fonds | Major Shareholder | Sell | 47,854 | $15.00 | $717,810.00 | 3,036,153 | |
| 4/18/2024 | De Solidarite Des Travai Fonds | Major Shareholder | Sell | 4,575 | $15.01 | $68,670.75 | 3,084,107 | |
| 12/29/2023 | Growth Opportunities F Forbion | Major Shareholder | Buy | 10,020 | $9.06 | $90,781.20 | 2,017,820 | |
| 12/27/2023 | Growth Opportunities F Forbion | Major Shareholder | Buy | 2,750 | $7.17 | $19,717.50 | 2,002,750 | |
enGene Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 10/16/2025 | PFS Partners LLC | 9,000 | $61K | 0.0% | N/A | 0.018% |  |
| 8/15/2025 | Adage Capital Partners GP L.L.C. | 1,000,000 | $3.64M | 0.0% | -36.4% | 1.957% |  |
| 8/14/2025 | Paloma Partners Management Co | 10,319 | $38K | 0.0% | N/A | 0.020% |  |
| 8/14/2025 | Orbimed Advisors LLC | 677,977 | $2.47M | 0.1% | -24.0% | 1.327% |  |
| 8/13/2025 | Affinity Asset Advisors LLC | 77,000 | $0.28M | 0.0% | N/A | 0.151% |  |
| 8/13/2025 | Cresset Asset Management LLC | 10,000 | $36K | 0.0% | N/A | 0.020% |  |
| 8/12/2025 | Franklin Resources Inc. | 1,038,000 | $3.78M | 0.0% | -11.6% | 2.031% |  |
| 5/16/2025 | Adage Capital Partners GP L.L.C. | 1,571,642 | $7.04M | 0.0% | +2.7% | 3.083% |  |
| 5/16/2025 | ADAR1 Capital Management LLC | 23,799 | $0.11M | 0.0% | N/A | 0.047% |  |
| 5/15/2025 | MAI Capital Management | 78,067 | $0.35M | 0.0% | +11.0% | 0.153% |  |
| 2/19/2025 | Toronto Dominion Bank | 14,537 | $97K | 0.0% | N/A | 0.033% |  |
| 2/17/2025 | VR Adviser LLC | 5,046,414 | $33.56M | 2.3% | +41.5% | 11.412% |  |
| 2/17/2025 | Vestal Point Capital LP | 370,000 | $2.46M | 0.1% | N/A | 0.837% |  |
| 2/17/2025 | Two Sigma Investments LP | 35,866 | $0.24M | 0.0% | -9.5% | 0.081% |  |
| 2/17/2025 | Toronto Dominion Bank | 14,537 | $97K | 0.0% | N/A | 0.033% |  |
| 2/17/2025 | Sphera Funds Management LTD. | 560,000 | $3.72M | 0.7% | N/A | 1.266% |  |
| 2/17/2025 | Point72 Asset Management L.P. | 1,224,797 | $8.15M | 0.0% | +84.7% | 2.770% |  |
| 2/17/2025 | Orbimed Advisors LLC | 920,339 | $6.12M | 0.1% | N/A | 2.081% |  |
| 2/17/2025 | Omega Fund Management LLC | 526,357 | $3.50M | 2.9% | -51.1% | 1.190% |  |
| 2/17/2025 | Fcpm Iii Services B.V. | 9,632,561 | $64.06M | 10.9% | +11.0% | 21.783% |  |
| 2/17/2025 | Deep Track Capital LP | 4,557,575 | $30.31M | 1.1% | +74.8% | 10.307% |  |
| 2/17/2025 | Corton Capital Inc. | 23,601 | $0.16M | 0.1% | N/A | 0.053% |  |
| 2/17/2025 | Cubist Systematic Strategies LLC | 15,342 | $0.10M | 0.0% | +15.7% | 0.035% |  |
| 2/17/2025 | BVF Inc. IL | 2,106,037 | $14.01M | 0.5% | -6.4% | 4.763% |  |
| 2/14/2025 | Jane Street Group LLC | 14,038 | $93K | 0.0% | N/A | 0.032% |  |
| 2/14/2025 | Schonfeld Strategic Advisors LLC | 132,260 | $0.88M | 0.0% | -56.8% | 0.299% |  |
| 2/14/2025 | Blue Owl Capital Holdings LP | 3,159,975 | $21.01M | 5.0% | +3.3% | 7.146% |  |
| 2/14/2025 | Adage Capital Partners GP L.L.C. | 1,529,768 | $10.17M | 0.0% | -34.3% | 3.459% |  |
| 2/13/2025 | Marshall Wace LLP | 593,742 | $3.95M | 0.0% | -12.9% | 1.343% |  |
| 1/30/2025 | Vontobel Holding Ltd. | 10,417 | $69K | 0.0% | N/A | 0.024% |  |
| 11/27/2024 | Franklin Resources Inc. | 1,189,952 | $7.85M | 0.0% | +48.7% | 2.691% |  |
| 11/15/2024 | Point72 Asset Management L.P. | 663,000 | $4.38M | 0.0% | +1,410.3% | 1.499% |  |
| 11/4/2024 | Wolverine Asset Management LLC | 5,574 | $37K | 0.0% | N/A | 0.013% |  |
| 8/19/2024 | Point72 Asset Management L.P. | 43,900 | $0.41M | 0.0% | -76.0% | 0.099% |  |
| 8/16/2024 | Perceptive Advisors LLC | 800,000 | $7.54M | 0.2% | -19.9% | 1.811% |  |
| 8/15/2024 | Blue Owl Capital Holdings LP | 2,449,827 | $23.10M | 6.4% | -0.5% | 5.547% |  |
| 8/14/2024 | Marshall Wace LLP | 764,645 | $7.21M | 0.0% | -4.4% | 1.731% |  |
| 8/14/2024 | Logos Global Management LP | 1,200,000 | $11.32M | 0.9% | +50.0% | 2.717% |  |
| 8/13/2024 | SR One Capital Management LP | 500,000 | $4.72M | 1.5% | N/A | 1.132% |  |
| 5/16/2024 | Janus Henderson Group PLC | 1,000,000 | $17.10M | 0.0% | N/A | 2.295% |  |
| 5/15/2024 | Altitude Crest Partners Inc. | 120,289 | $2.04M | 0.9% | N/A | 0.276% |  |
| 3/7/2024 | Fcpm Iii Services B.V. | 8,677,951 | $80.10M | 23.8% | N/A | 37.408% |  |
| 2/15/2024 | Omega Fund Management LLC | 1,131,175 | $10.44M | 8.5% | N/A | 4.876% |  |
| 2/15/2024 | BVF Inc. IL | 2,251,037 | $20.78M | 0.5% | N/A | 9.703% |  |
| 2/7/2024 | Vivo Capital LLC | 678,705 | $6.26M | 0.5% | N/A | 2.925% |  |
Data available starting January 2016
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More on enGene
Volume
212,817 shs
Average Volume
290,858 shs
Market Capitalization
$310.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of enGene?
Who are the major institutional investors of enGene?
Which institutional investors are buying enGene stock?
In the previous quarter, ENGN stock was purchased by institutional investors including:
- PFS Partners LLC
Within the previous year, these company insiders have bought enGene stock:
- De Solidarite Des Travai Fonds (Major Shareholder)
- Growth Opportunities F Forbion (Major Shareholder)
Learn More investors buying enGene stock.